Biocon Secures Earliest Global Launch Dates for Biosimilar Pertuzumab via Genentech Settlement
Biocon Ltd 路 Others (Uncategorized) 路 14 Oct 2026, 1:55 pm
Biocon Secures Earliest Global Launch Dates for Biosimilar Pertuzumab via Genentech Settlement Biocon Limited has entered into a global settlement and licensing agreement with Genentech to resolve all pending patent disputes across the U.S., Canada, and other jurisdictions. The agreement secures earliest licensed launch dates for Pebrilzo, a biosimilar referencing Perjeta (Pertuzumab) for HER2-positive breast cancer. Biocon is licensed to launch Pebrilzo in the EU and UK in Q1 CY'27, the U.S. in Q3 CY'28, and Rest of the World markets across CY'26鈥揅Y'28, subject to regulatory approvals. Other financial terms remain confidential.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release 路 18 Nov 2026
- Press Release 路 16 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) 路 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 路 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call 路 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 路 04 Nov 2026
- Investor Presentation 路 04 Nov 2026
- Change in Senior Management Personnel 路 04 Nov 2026
